SeaStar Medical Holding Corporation (ICUCW)
ICUCWNASDAQ-CMMedical/Dental Instruments
$0.00840000
-0.0002 (-2.33%) today
Regular session, Nov 17, 2:44 PM ET
- Market cap
- $43.6k
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.00810000 to $0.0750
- Average volume
- –
- Previous close
- $0.00860000
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $420.0k | $495.0k | $615.0k | $635.0k |
| Gross profit | $408.0k | $449.0k | $561.0k | $587.0k |
| Operating income | -$3.02m | -$3.60m | -$3.79m | -$4.58m |
| Net income | -$2.90m | -$3.52m | -$3.73m | -$4.53m |
Last four quarters: revenue $2.17m, margin -678.2%, free cash flow –
News
8 latest- Stock Indices Plunge Amid Broad Market WeaknessBarchart · 5 minutes ago
- GreenTree Hospitality Group Ltd. Receives Continued Listing Notice from NYSEFintel · 9 minutes ago
- Proto Labs, Inc. Appoints Frank Klein to Board of DirectorsFintel · 9 minutes ago
- American Airlines Group Inc. Announces COO David G. Seymour to Step Down on December 31, 2026Fintel · 9 minutes ago
- Netflix Stock Is Down 36% and Wall Street Keeps Downgrading It. History Says That's a Mistake.The Motley Fool · 12 minutes ago
- Anthropic Jumped 17% in Its Debut. Here’s Why I’m Waiting to Buy ANT Stock.The Motley Fool · 18 minutes ago
- Interactive Strength Inc. Amends Exchange Agreements and Series R Preferred Stock TermsFintel · 18 minutes ago
- Purple Biotech Ltd Announces Preclinical Data on IM1240 at 38th EORTC-NCI-AACR SymposiumFintel · 18 minutes ago
The company
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical's first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- seastarmedical.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.